株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

マイクロバイオーム治療薬市場

Microbiome Therapeutics and Diagnostics Market (2nd Edition), 2017-2030

発行 ROOTS ANALYSIS 商品コード 350407
出版日 ページ情報 英文 450 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=110.15円で換算しております。
Back to Top
マイクロバイオーム治療薬市場 Microbiome Therapeutics and Diagnostics Market (2nd Edition), 2017-2030
出版日: ページ情報: 英文 450 Pages
概要

当レポートでは、マイクロバイオーム治療薬市場の現状と見通しについて調査し、開発段階・製品タイプ・適応症別による治療薬パイプライン、潜在的な治療領域における疫学・患者人口・利用可能な治療計画、近年の提携、マイクロバイオーム治療薬の普及見込み、および主要企業のプロファイルなどをまとめています。

第1章 序章

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • 微生物叢・マイクロバイオームの定義
  • ヒトマイクロバイオームの発見
  • ヒトマイクロバイオームプロジェクト (HMP)
  • ヒトマイクロバイオームの機能
  • 腸内フローラ
  • 乳児における微生物叢の発達
  • ヒトマイクロバイオームと病気の関係
  • マイクロバイオーム治療薬のニーズ
  • 糞便細菌製剤療法:健康的な腸内ミクロフローラを回復させる強力な手段

第4章 市場概要

  • 本章の概要
    • マイクロバイオーム治療薬の開発パイプライン
    • 糞便微生物叢移植の開発パイプライン
    • 診断アプリケーションの開発パイプライン
    • 医療食、サプリメントおよび消費財の開発パイプライン

第5章 KOL分析

  • 本章の概要
  • プロバイオティクス医薬品
  • プレバイオティクス医薬品
  • プロバイオティクス/プレバイオティクス医薬品のパイプライン開発

第6章 主な治療領域

  • 本章の概要
  • 胃腸 (GI) 疾患/消化器疾患
    • クロストリジウム-ディフィシル感染症 (CDI)
    • 過敏性腸症候群 (IBS)
  • 炎症性疾患
    • 潰瘍性結腸炎
    • クローン病
  • 代謝異常
    • 糖尿病
    • 肥満
  • 婦人科疾患
    • 細菌性膣炎 (BV)

第7章 ベンチャーキャピタルの関心

  • 本章の概要
  • マイクロバイオーム治療薬・診断の開発資金の事例
  • ベンチャーキャピタルの関心の高まり
  • 資金の例:資金タイプによる分布
  • 主要企業:資金事例の数による分布
  • 最も活発なVC企業/機関
  • 資金のほとんどは治療用途をターゲットに

第8章 近年のコラボレーション

  • 本章の概要
  • 提携モデル/合意
  • マイクロバイオーム治療薬:近年のコラボレーション
  • 分布:月/年度別
  • 分布:アプリケーションタイプ別
  • 分布:提携タイプ別
  • 複数のコラボレーションを用いる最も活発な企業

第9章 市場規模・機会分析

  • 本章の概要
  • 予測手法
  • マイクロバイオーム治療薬市場:主な前提条件
  • マイクロバイオーム治療薬市場:機会分析

第10章 企業プロファイル

  • 本章の概要
  • C3 Jian
  • Enterome Bioscience
  • Immuron
  • MicroBiome Therapeutics
  • OpenBiome
  • Osel
  • Rebiotix
  • Ritter Pharmaceuticals
  • Second Genome
  • Seres Therapeutics
  • Synthetic Biologics

第11章 結論

第12章 専門家へのインタビュー

第13章 付録1:表データ

第14章 付録2:企業・組織リスト

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: RA10087

Microbiome therapeutics represent a new frontier in the field of medicine. The human microbiome is characterized by more than 100 trillion commensal, symbiotic and pathogenic microorganisms that colonize the gut, mouth, skin and various other parts of the body. Majority of these microorganisms benefit humans by supplementing them with traits that they do not otherwise possess; these include the capability to metabolize complex carbohydrates and prevention of growth of pathogens. However, some of these microorganisms are pathogenic in nature or have the capability to transform into disease-causing agents. In fact, an imbalance in the human microbiome, or dysbiosis, has been shown to be associated with various diseases, such as Clostridium difficile infections (CDIs), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), diabetes and other chronic conditions.

In addition to the existing treatment plans for the above mentioned health conditions, approaches related to modifying the natural microbiome of an individual, either by adding / removing individual microbes or entire microbial communities, have been shown to demonstrate significant health benefits. Such therapies offer unique advantages over traditional small molecules or biologics based treatment regimens. In fact, one of the driving forces for developing microbiome therapeutics is to avoid the harmful side-effects of antibiotic therapies; some of these side-effects include disruption of protective / beneficial microbiota and the generation of antibiotic-resistant pathogenic strains.

Currently, there are many probiotics, prebiotics, and medical foods and supplements that are commercially available as over the counter (OTC) products. Such products claim to be capable of preventing a number of diseases by restoring the human microbiome to its natural (normal) state; however, these products cannot be used as a replacement for medication or as a treatment option. At the same time, several drug / therapy candidates that claim to be capable of modifying / manipulating the microbiome in order to provide therapeutic benefits are being developed as prescription drugs. With a rich development pipeline, microbiome therapeutics has managed to capture the interest of several strategic investors and venture capital firms. We believe, if approved, these therapeutics are likely to change the treatment modalities for several indications across GI disorders, metabolic disorders, dermatological indications and inflammatory diseases.

Synopsis:

The ‘Microbiome Therapeutics and Diagnostics Market (2nd Edition), 2017-2030’ report provides a comprehensive study on the current landscape and the future outlook of the growing pipeline of products (therapeutics and diagnostics) in this area. The rising popularity and potential within this domain can be correlated with the exponential increase in the number of citations of the term microbiome on PubMed, the popular scientific literature resource; the number increased from 959 citations in 2003 to 33,809 citations in the first half of 2017.

While the field has captured the interest of several companies and investors alike, no approved microbiome drugs are yet available in the market; FMT is currently the only commercially available microbiome based therapy. In addition, a few microbiome diagnostic tests are commercially available for the detection of gastrointestinal (GI) disorders and inflammatory diseases. Having said that, the development pipeline of microbiome therapeutics has several promising candidates that are likely to result in commercial success stories in the foreseen future.

The report is primarily focused on prescription drugs, probiotic drugs and prebiotic drugs, which are being developed in this domain. In addition, we have captured FMT products and screening / diagnostic tests that are already available / under development. During the course of our study, we identified over 170 microbiome therapeutics and close to 25 microbiome diagnostics across various stages of development; majority of the therapeutic products are currently in early phases of development. Amongst other elements, the report features:

  • A review of the current status of the market with respect to the microbiome therapeutics pipeline, providing information on the developers, phase of development (clinical, preclinical or discovery stage) of various product candidates, product type, target indication(s) and therapeutic areas. In addition, the report highlights the growing pipeline of microbiome based diagnostics and FMTs.
  • An assessment of the emerging role of big data in microbiome therapeutics, highlighting the development and implementation of various algorithms / tools to analyze data generated from research, in order to understand the relationship between the microbiome and the host.
  • A discussion on potential target disease indications across popular therapeutic areas includingmetabolic disorders, GI disorders, oncological diseases, dermatological diseases, inflammatory disorders, and women disorders. It includes detailed disease descriptions, epidemiology, current treatment plans, side effects of current treatment options and upcoming microbiome therapies.
  • Elaborate profiles of clinical stage companies (selected based on the number of pipeline products and year of establishment); each profile features an overview of the company, its financial performance, product portfolio, detailed information on advanced stage pipeline candidates (featuring a drug overview, clinical development plan and clinical trial results) and a comprehensive future outlook.
  • A detailed analysis of the database presented as three schematic representations; a world map depicting the most active geographies in terms of the presence of companies developing microbiome therapeutics, a heat map featuring the distribution of companies on the basis of their location, number of employees and phase of development of pipeline products, and a grid analysis of the microbiome therapeutics pipeline, wherein individual product candidates have been compared according to their respective target therapeutic areas and phases of development.
  • A social media analysis on the emerging trends and popularity of microbiome therapeutics on the social media platform, Twitter.
  • An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, license agreements, mergers and acquisitions, manufacturing and services agreements, and other relevant agreements.
  • An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants, and capital raised from IPOs and subsequent offerings, received by companies that are focused in this area.
  • A detailed discussion on the various steps involved in the development and manufacturing of microbiome therapeutics, featuring information on various players that offer contract manufacturing services, or have in-house manufacturing capabilities, and those that offer other contract services, such as screening, sequencing and characterization of the microbiome, related to microbiome therapeutics.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2017-2030. The research, analysis and insights presented in this report include potential sales of FMT therapies, drugs in late stages of development and diagnostics that are already approved, and those that are likely to receive approval in the near future. The base year for the report is 2017. To account for the uncertainties associated with the development of novel therapeutic classes and to add robustness to our model, we have provided three forecast scenarios portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in the report were influenced by discussions with senior stakeholders in the industry. These include James Burges (Executive Director, OpenBiome), Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic), Nikole E Kimes (Co-founder and Vice President, Siolta Therapeutics), Lee Jones (President and Chief Executive Officer, Rebiotix) and Colleen Cutcliffe (Co-founder and Chief Executive Officer, Whole Biome), JP Benya (Vice President, Business Development, Assembly Biosciences), Pierre-Alain Bandinelli (Chief Business Officer, Da Volterra), Gregory J Kuehn (Vice President, Business Development and Marketing, Metabiomics)and Dr. Mark Heiman (Chief Scientific Officer and Vice President, Research, MicroBiome Therapeutics). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights:

  • 1. Close to 66% of the microbiome therapeutic products are in preclinical stage of development while seven products are in advanced stages (phase II/III and above). These include (in alphabetical order) B244 (AOBiome), HOST-G904 (HOST Therabiomics), Oxabact® (OxThera), RBX2660 (Rebiotix), RP-G28 (Ritter Pharmaceuticals), SER-109 (Seres Therapeutics) and SYN-010 (Synthetic Biologics).
  • 2. The innovation in this market is largely driven by smaller players, most of which are start-ups. Some of the start-ups involved in the development of microbiome therapeutics include (in alphabetical order) Axial Biotherapeutics, Azitra, ClostraBio, Evelo Biosciences, HOST Therabiomics, MicroViable Therapeutics and Siolta Therapeutics. In addition, this domain has witnessed the establishment of several university spin-offs; examples include (in alphabetical order), A-mansia (University catholique de Louvain and Wageningen University), Nubiyota (University of Guelph) and Symberix (University of North Carolina).
  • 3. In addition to the start-ups, some large and mid-sized companies are driving the development of microbiome based therapies. Examples of the large and mid-sized companies that are active in this field are (in alphabetical order) Assembly Biosciences, Biose, Igen Biotech, Leadiant Biosciences, Merck, Novartis, OxThera and Seres Therapeutics. Some of the other large pharmaceutical players, such as Johnson & Johnson, Pfizer and Roche, have been actively funding the initiatives of companies engaged in development of microbiome therapeutics.
  • 4. Several industry and non-industry players are contributing to the development of the FMT pipeline. Currently, FMTs are approved for the treatment of recurrent CDI (not responding to standard care). Prominent players that are developing FMTs include OpenBiome, Bright Medicine Clinic and Advancing Bio.
  • 5. Close to 20 microbiome based diagnostics are already available in the market; these are capable of diagnosing IBS and dysbiosis of the gut. Examples of companies that have a diagnostic product available in the market include (in alphabetical order) Genetic Analysis, Genova Diagnostics, IS-diagnostics and Wellmicro. Other prominent players involved in this segment include (in alphabetical order) Enterome bioscience, C3J Therapautics and Vaiomer.
  • 6. Over 115 funding instances to support the development of microbiome therapeutics, diagnostic tests and FMTs have been reported between 2011 and May 2017. 49% of the total investment is in the form of venture capital financing; Seventure Partners has emerged as one of the prominent investors in this domain. In addition, 26% of the funding instances were related to seed, debt financing and grants. In the given period, three companies in this domain went public; these include Seres Therapeutics (2015, USD 139.3 million), Ritter Pharmaceuticals (2015, USD 20 million) and 4D Pharma (2014, USD 27.6 million).
  • 7. Close to 110 partnerships were inked during the period 2013 to May 2017. Of these, approximately 60% were signed for early R&D activities. Other popular types of collaborations in this domain include licensing agreements (product / technology) (14%), followed by mergers and acquisitions (9%). Recent examples of mergers and acquisitions include Mirna Therapeutics (Synlogic, May 2017), Epiva Biosciences (Evelo Sciences, July 2016) and Tucana Health (4D Pharma, April 2016).
  • 8. Overall, the microbiome therapeutics and diagnostics market is anticipated to grow at a healthy pace. Of the total market, the therapeutics segment is expected to occupy a share of close to 79% (in 2030), growing at an annualized growth rate of 84% between 2019 and 2030. As more microbiome therapeutics move to higher phases of development, the combined contribution of probiotic drugs and prebiotic drugs is likely to be close to 48% of the total market. This will be driven by the likely approval of a number of clinical stage products currently in the development pipeline.
  • 9. GI disorders is likely to be the key focus of developers in the short-midterm (close to 60% share by 2025). However, the next wave of growth is expected to be led by developments focused on products targeting metabolic disorders (including diabetes, NASH, lactose intolerance) and oncological disorders; products being developed for these therapeutic areas are expected to be approved and achieve wider adoption amongst the patient populations; by 2030, we expect metabolic and oncological disorders to contribute a share of 44% and 10%, respectively, of the total market.

Research Methodology:

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high level view on the likely evolution of the microbiome therapeutics market in the short-mid and long term.

Chapter 3 provides a general introduction to the underlying concepts on human microbiota. In addition to reviewing the functions of the microbiota, we have also discussed key aspects of the Human Microbiome Project and the diseases caused by an imbalance in the microbiome. Further, we have discussed the various types of probiotic and prebiotic drugs that are under development. In addition, the chapter provides an overview of the regulatory landscape for live biotherapeutic products (LBPs), which are likely to be approved in the coming years.

Chapter 4 includes information on over 170 product candidates that are currently in different stages of development (both clinical and preclinical / discovery). It features a detailed and comprehensive analysis of the pipeline molecules, highlighting the key therapeutic areas, product type, phases of development, geographical locations of developers, and leading players in the field of microbiome therapeutics.

Chapter 5 provides detailed company and drug profiles of active players (selected based on the number of pipeline products and year of establishment) in the microbiome therapeutics market. Each company profile includes an overview of the company, its financial performance (wherever available) and details of its product portfolio. In addition, we have provided detailed profiles of advanced phase drugs (phase II and above); each drug profile contains information on its clinical development status, clinical trial endpoints and key clinical trial results.

Chapter 6 provides details on the microbiome diagnostics pipeline, featuring a comprehensive analysis of the various types of products that are being developed within this segment of the microbiome market. The chapter also contains brief profiles of various microbiome diagnostics developers covering information, such as technology platforms and products being developed by these companies.

Chapter 7 presents a brief history of FMTs, a review of the current market landscape (in terms of industry pipeline and non-industry clinical studies) of such products, and details on administration procedures and clinical relevance. In addition, the chapter provides an overview of the regulatory landscape related to these therapies. Further, it includes brief profiles on the various stool banks that have been established over the years.

Chapter 8 presents information on the role of big data and its applications in the healthcare industry. Further, the chapter elaborates on the use of big data analytics to understand microbiome consortium and to design microbiome based therapeutics. It also contains brief profiles of companies offering big data services related to microbiome.

Chapter 9 highlights the potential target indications (segregated by therapeutic areas) for microbiome therapeutics that are currently the prime focus of companies developing these drugs. These therapeutic areas include (in alphabetical order) dermatological diseases, GI disorders, inflammatory disorders, metabolic disorders, oncology, and women disorders. The chapter also provides details on disease epidemiology, currently available treatment options for each indication and their likely side effects.

Chapter 10 presents details on various investments and grants received by companies that are focused in this domain. It also includes an analysis of the funding instances that have taken place in the period between 2011 and 2017 (May), highlighting the growing interest of the venture capital community and other strategic investors in this market.

Chapter 11 features an elaborate discussion and analysis of the collaborations and partnerships that have been forged amongst players in this market. We have also discussed the various partnership models and the most common forms of deals / agreements that have been established in the period between 2013 and 2017 (May).

Chapter 12 provides details on various players that offer contract manufacturing services for microbiome based products, or possess the necessary capabilities and infrastructure to manufacture such products in-house. The chapter also provides information on companies that provide other affiliated contract services, such as screening, sequencing and characterization of the microbiome.

Chapter 13 highlights the likely growth of the market of microbiome therapeutics, diagnostics and FMTs from 2017-2030. We have segregated the financial opportunity in this domain by applications (therapeutics, diagnostics and FMTs) product types (probiotic drugs, prebiotic drugs and other drugs), key therapeutic areas, geographies and leading players. The projections related to the market's future are backed by robust data and credible inputs from primary research. Due to the uncertain nature of the market, we have presented three different tracks representing conservative, base and optimistic scenarios of the evolution of the market.

Chapter 14 is a compilation of key insights gathered from the study. It features a schematic representation on a world map, highlighting the key regional hubs driving the research on microbiome therapeutics. Further, we have provided a heat map analysis of the distribution of companies involved in this field, based on their location (continent-wise distribution), number of employees and phase of development of pipeline molecules (clinical and / or preclinical). The chapter also features a comprehensive grid analysis of the various therapeutic product candidates, highlighting their respective target therapeutic areas and phases of development. In addition, the chapter includes a discussion on the emerging trends and the growing popularity of microbiome therapeutics, as observed on the social media platform, Twitter, over the period between January 2013 and June 2017.

Chapter 15 is a summary of the overall report, featuring a list of key takeaways from the research and our independent opinion on the nature and potential of the microbiome therapeutics market.

Chapter 16 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. These include James Burges (Executive Director, OpenBiome), Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic), Nikole E Kimes (Co-founder and Vice President, Siolta Therapeutics), Lee Jones (President and Chief Executive Officer, Rebiotix) and Colleen Cutcliffe (Co-founder and Chief Executive Officer, Whole Biome), JP Benya (Vice President, Business Development, Assembly Biosciences), Pierre-Alain Bandinelli (Chief Business Officer, Da Volterra), Gregory J Kuehn (Vice President, Business Development and Marketing, Metabiomics) and Dr. Mark Heiman (Chief Scientific Officer and Vice President, Research, MicroBiome Therapeutics).

Chapter 17 is an appendix, which provides a list of microbiome based probiotic supplements, medical foods and consumer products.

Chapter 18 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 19 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Context and Background
  • 3.2. Defining Microbiota and Microbiome
    • 3.2.1. Discovery of the Human Microbiome
    • 3.2.2. Functions of the Human Microbiome
  • 3.3. The Gut Flora
    • 3.3.1. Physiological Role of Gut Flora
    • 3.3.2. Factors Affecting the Gut Flora
      • 3.3.2.1. Age and Pregnancy
      • 3.3.2.2. Use of Antibiotics
      • 3.3.2.3. Stress
      • 3.3.2.4. Intake of Certain Food Products
      • 3.3.2.5. Lifestyle
  • 3.4. Relationship between the Human Microbiome and Disease
    • 3.4.1. Obesity
    • 3.4.2. Type-2 Diabetes
    • 3.4.3. Cancer
    • 3.4.4. Inflammatory Bowel Disease (IBD)
    • 3.4.5. Parkinson's Disease
    • 3.4.6. Other Disease Indications
  • 3.5. Impact of Microbiota on Drug Pharmacokinetics
  • 3.6. Impact of Microbiota on Clinical Outcomes
  • 3.7. The Human Microbiome Project
    • 3.7.1. Project Approach
    • 3.7.2. Project Initiatives
    • 3.7.3. Project Achievements
  • 3.8. Microbiome Therapeutics
    • 3.8.1. Probiotics
      • 3.8.1.1. Beneficial Strains
      • 3.8.1.2. Key Therapeutic Areas
      • 3.8.1.3. Side Effects
    • 3.8.2. Prebiotics
      • 3.8.2.1. Source of Prebiotics
      • 3.8.2.2. Types of Prebiotics
      • 3.8.2.3. Key Therapeutic Areas
      • 3.8.2.4. Side Effects
  • 3.9. Regulatory Guidelines for Live Biotherapeutic Products (LBPs)

4. COMPETITIVE LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Microbiome Therapeutics: A Robust Development Pipeline
  • 4.3. Pipeline Analysis
    • 4.3.1. Distribution by Phase of Development
    • 4.3.2. Distribution by Type of Product
    • 4.3.3. Distribution by Geography
    • 4.3.4. Distribution by Therapeutic Area
    • 4.3.5. Active Industry Players

5. COMPANY PROFILES

  • 5.1. Chapter Overview
  • 5.2. 4D Pharma
    • 5.2.1. Company Overview
    • 5.2.2. Financial Performance
    • 5.2.3. Product Portfolio
    • 5.2.4. Future Outlook
  • 5.3. AOBiome
    • 5.3.1. Company Overview
    • 5.3.2. Financial Performance
    • 5.3.3. Product Portfolio
      • 5.3.3.1. B244: Key Insights
    • 5.3.4. Future Outlook
  • 5.4. Assembly Biosciences
    • 5.4.1. Company Overview
    • 5.4.2. Financial Performance
    • 5.4.3. Product Portfolio
    • 5.4.4. Future Outlook
  • 5.5. C3J Therapeutics
    • 5.5.1. Company Overview
    • 5.5.2. Financial Performance
    • 5.5.3. Product Portfolio
      • 5.5.3.1. C16G2: Key Insights
      • 5.5.3.2. Other Pipeline Drugs
    • 5.5.4. Future Outlook
  • 5.6. Enterome bioscience
    • 5.6.1. Company Overview
    • 5.6.2. Financial Performance
    • 5.6.3. Product Portfolio
      • 5.6.3.1. EB8018: Key Insights
      • 5.6.3.2. Other Pipeline Drugs
    • 5.6.4. Future Outlook
  • 5.7. HOST Therabiomics
    • 5.7.1. Company Overview
    • 5.7.2. Product Portfolio
      • 5.7.2.1. HOST-G904: Key Insights
      • 5.7.2.2. Other Pipeline Drugs
    • 5.7.3. Future Outlook
  • 5.8. Osel
    • 5.8.1. Company Overview
    • 5.8.2. Product Portfolio
      • 5.8.2.1. Lactin-V: Key Insights
      • 5.8.2.2. Other Pipeline Drugs
    • 5.8.3. Future Outlook
  • 5.9. Rebiotix
    • 5.9.1. Company Overview
    • 5.9.2. Product Portfolio
      • 5.9.2.1. RBX2660: Key Insights
      • 5.9.2.2. Other Pipeline Products
    • 5.9.3. Future Outlook
  • 5.10. Ritter Pharmaceuticals
    • 5.10.1. Company Overview
    • 5.10.2. Financial Performance
    • 5.10.3. Product Portfolio
      • 5.10.3.1. RP-G28: Key Insights
    • 5.10.4. Future Outlook
  • 5.11. Second Genome
    • 5.11.1. Company Overview
    • 5.11.2. Financial Performance
    • 5.11.3. Second Genome Solutions
    • 5.11.4. Product Portfolio
      • 5.11.4.1. SGM-1019: Key Insights
    • 5.11.5. Future Outlook
  • 5.12. Seres Therapeutics
    • 5.12.1. Company Overview
    • 5.12.2. Financial Performance
    • 5.12.3. Product Portfolio
      • 5.12.3.1. SER-109: Key Insights
      • 5.12.3.2. SER-262: Key Insights
      • 5.12.3.3. SER-287: Key Insights
      • 5.12.3.4. Other Pipeline Drugs
    • 5.12.4. Future Outlook
  • 5.13. Synlogic
    • 5.13.1. Company Overview
    • 5.13.2. Financial Performance
    • 5.13.3. Technology Platform
    • 5.13.4. Product Portfolio
    • 5.13.5. Future Outlook
  • 5.14. Synthetic Biologics
    • 5.14.1. Company Overview
    • 5.14.2. Financial Performance
    • 5.14.3. Product Portfolio
      • 5.14.3.1. SYN-010: Key Insights
      • 5.14.3.2. SYN-004: Key Insights
      • 5.14.3.3. Other Pipeline Drugs
    • 5.14.4. Future Outlook

6. MICROBIOME DIAGNOSTICS

  • 6.1. Chapter Overview
  • 6.2. Introduction
  • 6.3. Microbiome Diagnostics and Next Generation Sequencing
  • 6.4. Competitive Landscape
    • 6.4.1. Analysis by Phase of Development
    • 6.4.2. Analysis by Geography
    • 6.4.3. Analysis by Therapeutic Area
  • 6.5. Company Profiles
    • 6.5.1. Enterome bioscience
  • 6.5.2. Vaiomer

7. FECAL MICROBIOTA THERAPY

  • 7.1. Introduction
  • 7.2. FMT: Historical Overview
  • 7.3. FMT: Administration Procedure and Clinical Relevance
    • 7.3.1. Donor Selection
    • 7.3.2. FMT Procedure
    • 7.3.3. Proposed Benefits
    • 7.3.4. Consequences and Adverse Events
    • 7.3.5. Clinical Guidelines
  • 7.4. FMT: Regulatory Guidelines
  • 7.5. Insurance Coverage
  • 7.6. Competitive Landscape
    • 7.6.1. Pipeline (Industry Participants)
    • 7.6.2. Clinical Trials (Non-Industry Participants)
      • 7.6.2.1. Clinical Trials: Analysis by Trial Initiation Period
      • 7.6.2.2. Clinical Trials: Analysis by Phase of Development
      • 7.6.2.3. Clinical Trials: Analysis by Recruitment Status
      • 7.6.2.4. Clinical Trials: Analysis by Indication
  • 7.7. Stool Banks: Key Players
    • 7.7.1. OpenBiome
      • 7.7.1.1. Overview
      • 7.7.1.2. Financial Performance
      • 7.7.1.3. Fecal Microbiota Preparations
    • 7.7.2. AdvancingBio
      • 7.7.2.1. Overview
      • 7.7.2.2. Fecal Microbiota Preparations
    • 7.7.3. Asia Microbiota Bank
      • 7.7.3.1. Overview
      • 7.7.3.2. Human Microbiota Transfer (HMT): Next Generation FMT

8. BIG DATA AND MICROBIOME THERAPEUTICS

  • 8.1. Chapter Overview
  • 8.2. Big Data
  • 8.3. Internet of Things
  • 8.4. Interest in Big Data: A Growing Trend
  • 8.5. Application Areas of Big Data
  • 8.6. Big Data in Microbiome Research
    • 8.6.1. Overview
    • 8.6.2. Challenges in Microbiome and Big Data Management
    • 8.6.3. National Microbiome Data Center
  • 8.7. Big Data for Microbiome Research: Key Players
    • 8.7.1. Human Longevity
      • 8.7.1.1. Overview
      • 8.7.1.2. Technology and Services
      • 8.7.1.3. Other Information
    • 8.7.2. Resilient Biotics
      • 8.7.2.1. Overview
      • 8.7.2.2. Technology and Services
    • 8.7.3. Resphera Biosciences
      • 8.7.3.1. Overview
      • 8.7.3.2. Technology and Services

9. KEY THERAPEUTIC AREAS

  • 9.1. Chapter Overview
  • 9.2. Metabolic Diseases
    • 9.2.1. Diabetes
      • 9.2.1.1. Disease Description
      • 9.2.1.2. Epidemiology
      • 9.2.1.3. Current Treatment Options
      • 9.2.1.4. Side Effects of Current Treatment Options
      • 9.2.1.5. Microbiome Therapies
    • 9.2.2. Obesity
      • 9.2.2.1. Disease Description
      • 9.2.2.2. Epidemiology
      • 9.2.2.3. Current Treatment Options
      • 9.2.2.4. Microbiome Therapies
    • 9.2.3. Lactose Intolerance
      • 9.2.3.1. Disease Description
      • 9.2.3.2. Epidemiology
      • 9.2.3.3. Current Treatment Options
      • 9.2.3.4. Microbiome Therapies for
    • 9.2.4. Nonalcoholic Steatohepatitis (NASH)
      • 9.2.4.1. Disease Description
      • 9.2.4.2. Epidemiology
      • 9.2.4.3. Current Treatment Options
      • 9.2.4.4. Microbiome Therapies
    • 9.2.5. Primary Hyperoxaluria
      • 9.2.5.1. Disease Description
      • 9.2.5.2. Epidemiology
      • 9.2.5.3. Current Treatment Options
      • 9.2.5.4. Microbiome Therapies
  • 9.3. Gastrointestinal (GI) Disorders
    • 9.3.1. Clostridium difficile Infections (CDIs)
      • 9.3.1.1. Disease Description
      • 9.3.1.2. Epidemiology
      • 9.3.1.3. Current Treatment Options
      • 9.3.1.4. Side Effects of Current Treatment Options
      • 9.3.1.5. Microbiome Therapies
    • 9.3.2. Irritable Bowel Syndrome (IBS)
      • 9.3.2.1. Disease Description
      • 9.3.2.2. Epidemiology
      • 9.3.2.3. Current Treatment Options
      • 9.3.2.4. Microbiome Therapies
  • 9.4. Oncological Indications
    • 9.4.1. Lung Cancer
      • 9.4.1.1. Disease Description
      • 9.4.1.2. Epidemiology
      • 9.4.1.3. Current Treatment Options
      • 9.4.1.4. Side Effects of Current Treatment Options
      • 9.4.1.5. Microbiome Therapies
    • 9.4.2. Colorectal Cancer
      • 9.4.2.1. Disease Description
      • 9.4.2.2. Epidemiology
      • 9.4.2.3. Current Treatment Options
      • 9.4.2.4. Side Effects of Current Treatment Options
      • 9.4.2.5. Microbiome Therapies
  • 9.5. Dermatological Disorders
    • 9.5.1. Acne Vulgaris
      • 9.5.1.1. Disease Description
      • 9.5.1.2. Epidemiology
      • 9.5.1.3. Current Treatment Options
      • 9.5.1.4. Side Effects of Current Treatment Options
      • 9.5.1.5. Microbiome Therapies
  • 9.6. Inflammatory Diseases
    • 9.6.1. Ulcerative Colitis
      • 9.6.1.1. Disease Description
      • 9.6.1.2. Epidemiology
      • 9.6.1.3. Current Treatment Options
      • 9.6.1.4. Side Effects of Current Treatment Options
      • 9.6.1.5. Microbiome Therapies
    • 9.6.2. Crohn's Disease
      • 9.6.2.1. Disease Description
      • 9.6.2.2. Epidemiology
      • 9.6.2.3. Current Treatment Options
      • 9.6.2.4. Side Effects of Current Treatment Options
      • 9.6.2.5. Microbiome Therapies
  • 9.7. Women Disorders
    • 9.7.1. Bacterial Vaginosis (BV)
      • 9.7.1.1. Disease Description
      • 9.7.1.2. Epidemiology
      • 9.7.1.3. Current Treatment Options
      • 9.7.1.4. Side Effects of Current Treatment Options
      • 9.7.1.5. Microbiome Therapies

10. VENTURE CAPITAL FUNDING

  • 10.1. Chapter Overview
  • 10.2. Types of Funding
  • 10.3. Microbiome Therapeutics and Diagnostics Investments: Funding Instances
  • 10.4. Microbiome Therapeutics and Diagnostics Investments: Analysis
    • 10.4.1. Analysis by Cumulative Number of Instances
    • 10.4.2. Analysis by Leading Players
    • 10.4.3. Analysis by Type of Product
  • 10.5. Microbiome Therapeutics and Diagnostics Investments: Most Active Investors

11. PARTNERSHIPS AND COLLABORATIONS

  • 11.1. Chapter Overview
  • 11.2. Partnership Models
  • 11.3. Microbiome Therapeutics and Diagnostics Partnerships: Instances
  • 11.4. Microbiome Therapeutics and Diagnostics Partnerships: Analysis
    • 11.4.1. Analysis by Year of Partnership
    • 11.4.2. Analysis by Type of Partnership
    • 11.4.3. Analysis by Therapeutic Area
    • 11.4.4. Analysis by Type of Product
  • 11.5. Microbiome Therapeutics and Diagnostics Partnerships: Most Active Companies

12. CONTRACT SERVICES FOR MICROBIOME THERAPEUTICS

  • 12.1. Chapter Overview
  • 12.2. Key Manufacturing Steps
  • 12.3. Key Manufacturing Challenges
  • 12.4. Contract and In-house Manufacturers
  • 12.5. Contract Research Organizations
  • 12.6. Recent Collaborations

13. MARKET SIZE AND OPPORTUNITY ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Forecast Methodology
  • 13.3. Input Data and Key Assumptions
  • 13.4. Overall Microbiome Market, 2017-2030
  • 13.5. Overall Microbiome Market: Distribution by Application
  • 13.6. Overall Microbiome Market: Distribution by Geography
  • 13.7. Microbiome Therapeutics Market: Distribution by Product Type
  • 13.8. Microbiome Therapeutics Market: Distribution by Leading Players
  • 13.9. Microbiome Therapeutics Market: Distribution by Therapeutic Area

14. KEY INSIGHTS

  • 14.1. Chapter Overview
  • 14.2. Microbiome Therapeutics: Regional Landscape
  • 14.3. Microbiome Therapeutics: Heat Map Analysis
  • 14.4. Microbiome Therapeutics: Grid Analysis
  • 14.5. Microbiome Therapeutics: Social Media Analysis
    • 14.5.1. Yearly Trends on Twitter
    • 14.5.2. Popular Keywords on Twitter

15. CONCLUSION

  • 15.1. Microfloral Imbalance is Suspected to be the Root Cause of a Number of Chronic Disorders, Antibiotic Overuse is the Primary Cause of Microbiota Disruption
  • 15.2. Microbiome Therapies Aid in Preserving Beneficial Microflora, Thereby Helping in Disease Prevention and Cure
  • 15.3. Start-ups, Assisted by Investment Activity from Both Private and Public Investors, are Spearheading the Innovation in this Domain
  • 15.4. Active Involvement of Regulatory Authorities will Act as a Key Enabler for Expedited Approval and Increased Market Penetration
  • 15.5. Partnerships, Primarily to Support R&D Activities, are Indicative of a Lucrative Future Potential
  • 15.6. Backed by a Robust Pipeline, the Market is Poised to Revolutionize the Treatment of a Myriad of Clinical Conditions and Witness Remarkable Growth in the Long Term

16. INTERVIEW TRANSCRIPTS

  • 16.1. Chapter Overview
  • 16.2. James Burgess, Executive Director, OpenBiome
  • 16.3. Veronika Oudova, Co-founder and Chief Executive Officer, S-Biomedic
  • 16.4. Nikole E Kimes, Co-founder and Vice President, Siolta Therapeutics
  • 16.5. Colleen Cutcliffe, Co-founder and Chief Executive Officer, Whole Biome
  • 16.6. JP Benya, Vice President, Business Development, Assembly Biosciences
  • 16.7. Pierre-Alain Bandinelli, Chief Business Officer, Da Volterra
  • 16.8. Gregory J Kuehn, Vice President, Business Development and Marketing, Metabiomics
  • 16.9. Mark Heiman, Vice President of Research and Chief Scientific Officer, MicroBiome Therapeutics
  • 16.10. Lee Jones, President and Chief Executive Officer, Rebiotix

17. APPENDIX: LIST OF CONSUMER PRODUCTS, MEDICAL FOODS AND SUPPLEMENTS

18. APPENDIX: TABULATED DATA

19. APPENDIX: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures:

  • Figure 3.1: Factors Affecting the Gut Flora
  • Figure 3.2: Factors Affecting Gut Microbiota in Infants
  • Figure 3.3: Interventions Influencing Gut Microbiota
  • Figure 3.4: Human Microbiome Project: Key Achievements
  • Figure 3.5: Types of Microbiome Therapeutics
  • Figure 3.6: Microbiome Therapeutics: Design Approaches
  • Figure 3.7: Probiotics: Health Benefits
  • Figure 3.8: Probiotic Drugs: Modes of Action
  • Figure 3.9: Probiotic Drugs: Overview of Beneficial Bacterial Strains
  • Figure 4.1: Microbiome Therapeutics: Distribution by Stage and Phase of Development
  • Figure 4.2: Microbiome Therapeutics: Distribution by Type of Product
  • Figure 4.3: Microbiome Therapeutics: Distribution by Geography
  • Figure 4.4: Microbiome Therapeutics: Distribution by Therapeutic Area
  • Figure 4.5: Microbiome Therapeutics: Distribution by Key Therapeutic Area and Phase of Development
  • Figure 4.6: Microbiome Therapeutics: Active Industry Players
  • Figure 5.1: Competitive Landscape of Players Established Between 1994 and 2009
  • Figure 5.2: Competitive Landscape of Players Established Between 2010 and 2016
  • Figure 5.3: 4D Pharma: Funding Instances (USD Million)
  • Figure 5.4: 4D Pharma: Product Portfolio
  • Figure 5.5: AOBiome: Funding Instances (USD Million)
  • Figure 5.6: AOBiome: Product Portfolio
  • Figure 5.7: B244: Clinical Trial Timeline
  • Figure 5.8: Assembly Biosciences: Funding Instances (USD Million)
  • Figure 5.9: Assembly Biosciences: Product Portfolio
  • Figure 5.10: C3J Therapeutics: Funding Instances (USD Million)
  • Figure 5.11: C3J Therapeutics: Product Portfolio
  • Figure 5.12: Oral Formulations of C16G2: Advantages
  • Figure 5.13: C16G2: Clinical Trial Timeline
  • Figure 5.14: Enterome bioscience: Funding Instances (EUR Million)
  • Figure 5.15: Enterome bioscience: Product Portfolio
  • Figure 5.16: HOST Therabiomics: Product Portfolio
  • Figure 5.17: Osel: Product Portfolio
  • Figure 5.18: LACTIN-V: Clinical Trial Timeline
  • Figure 5.19: Rebiotix: Product Portfolio
  • Figure 5.20: RBX2660: Clinical Trial Timeline
  • Figure 5.21: Ritter Pharmaceuticals: Funding Instances (USD Million)
  • Figure 5.22: Ritter Pharmaceuticals: Product Portfolio
  • Figure 5.23: RP-G28: Clinical Trial Timeline
  • Figure 5.24: Second Genome: Funding Instances (USD Million)
  • Figure 5.25: Second Genome Solutions: End-to-End Microbiome Profiling Program
  • Figure 5.26: Second Genome: Product Portfolio
  • Figure 5.27: Seres Therapeutics: Funding Instances (USD Million)
  • Figure 5.28: Seres Therapeutics: Product Portfolio
  • Figure 5.29: SER-109: Clinical Trial Timeline
  • Figure 5.30: Synlogic: Funding Instances (USD Million)
  • Figure 5.31: Synlogic: Components of Synthetic Biotic™
  • Figure 5.32: Synlogic: Product Portfolio
  • Figure 5.33: Synthetic Biologics: Funding Instances (USD Million)
  • Figure 5.34: Synthetic Biologics: Product Portfolio
  • Figure 5.35: SYN-010: Clinical Trial Timeline
  • Figure 5.36: SYN-004: Clinical Trial Timeline
  • Figure 6.1: 16S rRNA Gene Sequence Analysis: Key Steps
  • Figure 6.2: Microbiome Diagnostics: Distribution by Phase of Development
  • Figure 6.3: Microbiome Diagnostics: Distribution by Geographical Location
  • Figure 6.4: Microbiome Diagnostics: Distribution by Therapeutic Area
  • Figure 7.1: Clinical Trials: Distribution by Trial Initiation Period (2013-2017)
  • Figure 7.2: Clinical Trials: Distribution by Phase of Development
  • Figure 7.3: Clinical Trials: Distribution by Recruitment Status
  • Figure 7.4: Clinical Trials: Distribution by Indication
  • Figure 7.5: OpenBiome: Revenues 2015, Distribution by Revenue Source (USD Million)
  • Figure 8.1: Big Data: The Three V's
  • Figure 8.2: Internet of Things: Framework
  • Figure 8.3: Internet of Things: Applications in Healthcare
  • Figure 8.4: Big Data: Google Trends
  • Figure 8.5: Big Data: Application Areas
  • Figure 8.6: Big Data: Opportunities in Healthcare
  • Figure 8.7: Big Data: Key Benefits for Pharmaceuticals and Biotechnology Products
  • Figure 8.8: Challenges in Microbiome and Big Data Management
  • Figure 9.1: CDIs: Distribution of Pipeline by Product Type and Development Stage
  • Figure 9.2: IBS: Distribution of Pipeline by Product Type and Development Stage
  • Figure 9.3: Ulcerative Colitis: Distribution of Pipeline by Product Type and Development Stage
  • Figure 9.4: Crohn's Disease: Distribution of Pipeline by Product Type and Development Stage
  • Figure 10.1: Microbiome Therapeutics and Diagnostics Investments: Cumulative Funding Instances, Pre-2011-2017
  • Figure 10.2: Microbiome Therapeutics and Diagnostics Investments: Cumulative Funding Amount, Pre-2011-2017 (USD Million)
  • Figure 10.3: Microbiome Therapeutics and Diagnostics Investments: Distribution by Type, Pre-2011-2017
  • Figure 10.4: Microbiome Therapeutics and Diagnostics Investments: Distribution by Total Amount Invested, Pre-2011-2017 (USD Million)
  • Figure 10.5: Microbiome Therapeutics and Diagnostics Investments: Distribution of Type of Funding Based on Amount Invested (USD Million)
  • Figure 10.6: Microbiome Therapeutics and Diagnostics Investments: Leading Players
  • Figure 10.7: Microbiome Therapeutics and Diagnostics Investments: Most Active Investors
  • Figure 10.8: Microbiome Therapeutics and Diagnostics Investments: Distribution by Type of Product
  • Figure 10.9: Microbiome Therapeutics and Diagnostics Investments: Amount Invested by Type of Product and Type of Investment, Pre-2011-2017 (USD Million)
  • Figure 11.1: Microbiome Therapeutics and Diagnostics Partnerships: Cumulative Trend (Pre-2013-2017)
  • Figure 11.2: Microbiome Therapeutics and Diagnostics Partnerships: Distribution by Type of Partnership
  • Figure 11.3: Microbiome Therapeutics and Diagnostics Partnerships: Distribution by Therapeutic Area
  • Figure 11.4: Microbiome Therapeutics and Diagnostics Partnerships: Distribution by Type of Product
  • Figure 11.5: Microbiome Therapeutics and Diagnostics Partnerships: Distribution by Most Active Companies
  • Figure 12.1: Manufacturing Microbiome Therapeutics: Key Steps
  • Figure 13.1: Overall Microbiome Market, 2017-2030 (USD Million)
  • Figure 13.2: Overall Microbiome Market: Distribution by Type of Application, 2017-2030 (USD Million)
  • Figure 13.3: Overall Microbiome Market: Distribution by Geography, 2020, 2025 and 2030 (USD Million)
  • Figure 13.4: Microbiome Therapeutics Market: Distribution by Therapeutic Areas, 2017-2030 (USD Million)
  • Figure 13.5: Microbiome Therapeutics Market: Market Attractiveness Analysis by Therapeutic Area, 2023-2030
  • Figure 13.6: Microbiome Therapeutics Market: Distribution by Product Type, 2020, 2025 and 2030 (USD Million)
  • Figure 13.7: Microbiome Therapeutics Market: Distribution by Leading Players, 2020, 2025 and 2030 (USD Million)
  • Figure 14.1: Microbiome Therapeutics: Regional Landscape
  • Figure 14.2: Microbiome Therapeutics: Heat Map Analysis
  • Figure 14.3: Microbiome Therapeutics: Grid Analysis
  • Figure 14.4: Social Media Analysis: Yearly Trends on Twitter, January 2013-June 2017
  • Figure 14.5: Social Media Analysis: Word Cloud Analysis, January 2013-June 2017
  • Figure 15.1: Microbiome Therapeutics: Developer Landscape
  • Figure 15.2: Microbiome Therapeutics: Key Therapeutic Areas
  • Figure 15.3: Overall Microbiome Market: Conservative, Base and Optimistic Forecast Scenarios, 2017-2030 (USD Billion)

List of Tables:

  • Table 3.1: Microbiota in the GI Tract
  • Table 3.2: Impact of Antibiotics on Intestinal Microflora
  • Table 3.3: Microorganisms Recognized as Class 1 Carcinogens by the IARC
  • Table 3.4: Relationship between Microbiome and Other Disease Indications
  • Table 3.5: Impact of Drug-Microbiome Interactions
  • Table 3.6: Foods Containing Prebiotics
  • Table 4.1: Microbiome Therapeutics: Clinical Pipeline
  • Table 4.2: Microbiome Therapeutics: Preclinical Pipeline
  • Table 4.3: Microbiome Therapeutics: Status Unknown
  • Table 5.1: B244: Clinical Trials
  • Table 5.2: B244: Clinical Trials Endpoints
  • Table 5.3: C16G2: Clinical Trials
  • Table 5.4: C16G2: Clinical Trials Endpoints
  • Table 5.5: HOST-G904: Clinical Trials
  • Table 5.6: LACTIN-V: Clinical Trials
  • Table 5.7: LACTIN-V: Clinical Trials Endpoints
  • Table 5.8: RBX2660: Clinical Trials
  • Table 5.9: RBX2660: Clinical Trials Endpoints
  • Table 5.10: RP-G28: Clinical Trials
  • Table 5.11: RP-G28: Clinical Trials Endpoints
  • Table 5.12: SER-109: Clinical Trials
  • Table 5.13: SER-109: Clinical Trials Endpoints
  • Table 5.14: SYN-010: Clinical Trials
  • Table 5.15: SYN-010: Clinical Trials Endpoints
  • Table 5.16: SYN-004: Clinical Trials
  • Table 5.17: SYN-004: Clinical Trials Endpoints
  • Table 6.1: Microbiome Diagnostics: Microbiome Testing Kits
  • Table 6.2: Microbiome Diagnostics: Development Pipeline
  • Table 7.1: FMT: Summary of Guidelines
  • Table 7.2: Summary of Insurance Coverage Payers
  • Table 7.3: FMT Therapies: Pipeline
  • Table 7.4: FMT: Clinical Trials Pipeline
  • Table 7.5: OpenBiome: Type of Formulations
  • Table 7.6: FMT and HMT: Differences in Processing
  • Table 8.1: Big Data and Microbiome: List of Companies
  • Table 8.2: Human Longevity: Partnerships and Collaborations
  • Table 9.1: Diabetes: Current Treatment Options
  • Table 9.2: Diabetes: Side Effects of Current Treatment Options
  • Table 9.3: Diabetes: Microbiome Therapeutics Pipeline
  • Table 9.4: Obesity: Side Effects of Current Treatment Options
  • Table 9.5: Obesity: Microbiome Therapeutics Pipeline
  • Table 9.6: Lactose Intolerance: Microbiome Therapeutics Pipeline
  • Table 9.7: NASH: Microbiome Therapeutics Pipeline
  • Table 9.8: Primary Hyperoxaluria: Microbiome Therapeutics Pipeline
  • Table 9.9: CDIs: Diagnostic Tests
  • Table 9.10: CDIs: Severity Scoring System and Treatment Options
  • Table 9.11: CDIs: Side Effects of Current Treatment Options
  • Table 9.12: CDIs: Microbiome Therapeutics Pipeline
  • Table 9.13: IBS: Current Treatment Options
  • Table 9.14: IBS: Microbiome Therapeutics Pipeline
  • Table 9.15: Lung Cancer: Side Effects of Current Treatment Options
  • Table 9.16: Lung Cancer: Microbiome Therapeutics Pipeline
  • Table 9.17: Colorectal Cancer: Side Effects of Current Treatment Options
  • Table 9.18: Colorectal Cancer: Microbiome Therapeutics Pipeline
  • Table 9.19: Acne Vulgaris: Current Treatment Options
  • Table 9.20: Acne Vulgaris: Side Effects of Current Treatment Options
  • Table 9.21: Acne Vulgaris: Microbiome Therapeutics Pipeline
  • Table 9.22: Ulcerative Colitis: Current Treatment Options
  • Table 9.23: Ulcerative Colitis: Side Effects of Current Treatment Options
  • Table 9.24: Ulcerative Colitis: Microbiome Therapeutics Pipeline
  • Table 9.25: Crohn's Disease: Current Treatment Options
  • Table 9.26: Crohn's Disease: Side Effects of Current Treatment Options
  • Table 9.27: Crohn's Disease: Microbiome Therapeutics Pipeline
  • Table 9.28: Bacterial Vaginosis: Current Treatment Options
  • Table 9.29: Bacterial Vaginosis: Side Effects of Current Treatment Options
  • Table 9.30: Women Disorders: Microbiome Therapeutics Pipeline
  • Table 10.1: Microbiome Therapeutics and Diagnostics Investments: Funding Instances, Pre-2011-2017
  • Table 10.2: Microbiome Therapeutics and Diagnostics Investments: Types of Funding Instances, Pre-2011-2017
  • Table 11.1: Microbiome Therapeutics and Diagnostics Partnerships: Instances
  • Table 12.1: Microbiome Therapeutics: Contract Manufacturers
  • Table 12.2: Microbiome Therapeutics: Contract Research Organizations
  • Table 13.1: Potential of Key Therapeutic Areas: Estimated Market Growth Rate
  • Table 13.2: Potential of Key Therapeutic Areas: Estimated Penetration (by 2030)
  • Table 18.1: Microbiome Therapeutics: Distribution by Stage and Phase of Development
  • Table 18.2: Microbiome Therapeutics: Distribution by Type of Product
  • Table 18.3: Microbiome Therapeutics: Distribution by Geography
  • Table 18.4: Microbiome Therapeutics: Distribution by Therapeutic Area
  • Table 18.5: Microbiome Therapeutics: Distribution by Key Therapeutic Area and Phase of Development
  • Table 18.6: Microbiome Therapeutics: Active Industry Players
  • Table 18.7: 4D Pharma: Funding Instances (USD Million)
  • Table 18.8: AOBiome: Funding Instances (USD Million)
  • Table 18.9: Assembly Biosciences: Funding Instances (USD Million)
  • Table 18.10: C3J Therapeutics: Funding Instances (USD Million)
  • Table 18.11: Enterome bioscience: Funding Instances (EUR Million)
  • Table 18.12: Ritter Pharmaceuticals: Funding Instances (USD Million)
  • Table 18.13: Second Genome: Funding Instances (USD Million)
  • Table 18.14: Seres Therapeutics: Funding Instances (USD Million)
  • Table 18.15: Synlogic: Funding Instances (USD Million)
  • Table 18.16: Synthetic Biologics: Funding Instances (USD Million)
  • Table 18.17: Microbiome Diagnostics: Distribution by Phase of Development
  • Table 18.18: Microbiome Diagnostics: Distribution by Geographical Location
  • Table 18.19: Clinical Trials: Distribution by Trial Initiation Period (2013-2017)
  • Table 18.20: Clinical Trials: Distribution by Phase of Development
  • Table 18.21: Clinical Trials: Distribution by Recruitment Status
  • Table 18.22: Clinical Trials: Distribution by Indication
  • Table 18.23: OpenBiome: Revenues 2015, Distribution by Revenue Source (USD Million)
  • Table 18.24: CDIs: Distribution by Therapeutic Area
  • Table 18.25: CDIs: Distribution of Pipeline by Product Type and Development Stage
  • Table 18.26: IBS: Distribution of Pipeline by Product Type and Development Stage
  • Table 18.27: Ulcerative Colitis: Distribution of Pipeline by Product Type and Development Stage
  • Table 18.28: Crohn's Disease: Distribution of Pipeline by Product Type and Development Stage
  • Table 18.29: Microbiome Therapeutics and Diagnostics Investments: Cumulative Funding Instances, Pre-2011-2017
  • Table 18.30: Microbiome Therapeutics and Diagnostics Investments: Cumulative Funding Amount, Pre-2011-2017 (USD Million)
  • Table 18.31: Microbiome Therapeutics and Diagnostics Investments: Distribution by Type, Pre-2011-2017
  • Table 18.32: Microbiome Therapeutics and Diagnostics Investments: Distribution by Total Amount Invested, Pre-2011-2017 (USD Million)
  • Table 18.33: Microbiome Therapeutics and Diagnostics Investments: Distribution of Type of Funding Based on Amount Invested (USD Million)
  • Table 18.34: Microbiome Therapeutics and Diagnostics Investments: Leading Players
  • Table 18.35: Microbiome Therapeutics and Diagnostics Investments: Most Active Investors
  • Table 18.36: Microbiome Therapeutics and Diagnostics Investments: Distribution by Type of Product
  • Table 18.37: Microbiome Therapeutics and Diagnostics Investments: Amount Invested by Type of Product and Type of Investment, Pre-2011-2017 (USD Million)
  • Table 18.38: Microbiome Therapeutics and Diagnostics Partnerships: Cumulative Trend (Pre-2013-2017)
  • Table 18.39: Microbiome Therapeutics and Diagnostics Partnerships: Distribution by Type of Partnership
  • Table 18.40: Microbiome Therapeutics and Diagnostics Partnerships: Distribution by Therapeutic Area
  • Table 18.41: Microbiome Therapeutics and Diagnostics Partnerships: Distribution by Type of Product
  • Table 18.42: Microbiome Therapeutics and Diagnostics Partnerships: Distribution by Most Active Companies
  • Table 18.43: Overall Microbiome Market: Conservative, Base and Conservative Scenario, 2017-2030 (USD Million)
  • Table 18.44: Overall Microbiome Market: Distribution by Type of Application, Conservative, Base and Conservative Scenario, 2017-2030 (USD Million)
  • Table 19.45: Overall Microbiome Market: Distribution Geography, 2020, 2025, 2030 (USD Million)
  • Table 18.46: Microbiome Therapeutics Market: Distribution by Therapeutic Areas, Conservative, Base and Conservative Scenario, 2017-2030 (USD Million)
  • Table 18.47: Microbiome Therapeutics Market: Market Attractiveness Analysis by Therapeutic Area, 2023-2030
  • Table 18.48: Microbiome Therapeutics Market: Distribution by Product Type, 2020, 2025, 2030 (USD Million)
  • Table 19.49: Microbiome Therapeutics Market: Distribution by Leading Players, 2020, 2025, 2030 (USD Million)
  • Table 19.50: Overall Microbiome Market: Conservative, Base and Optimistic Forecast Scenario, 2017-2030 (USD Billion)

Listed Companies:

The following companies and organizations have been covered in this report.

  • 1. 4D Pharma
  • 2. AbbVie
  • 3. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
  • 4. Accinov
  • 5. ActoGeniX (aquired by Intrexon)
  • 6. Admera Health
  • 7. Advanced Technology Ventures
  • 8. Advancing Bio
  • 9. Adveq
  • 10. Aetna
  • 11. Alaven Pharmaceutical
  • 12. Alexandria Venture Investments
  • 13. Allergan
  • 14. A-Mansia
  • 15. American College of Gastroenterology
  • 16. Amrita Therapeutics
  • 17. ANIP Acquisition Company
  • 18. AOBiome
  • 19. APC Microbiome Institute at University College Cork
  • 20. Aptalis
  • 21. Arena Pharmaceuticals
  • 22. ARTPred
  • 23. Asia Microbiota Bank
  • 24. Assembly Biosciences
  • 25. AstraZeneca
  • 26. Atlas Venture
  • 27. Auto-ID Labs
  • 28. Aventis Pharma
  • 29. Avid Biotics
  • 30. Axial Biotherapeutics
  • 31. Azabu University
  • 32. Azitra
  • 33. B.V. Patel Pharmaceutical Education & Research Development (PERD) Centre
  • 34. Bacs-Kiskun Megyei Korhaz
  • 35. Bayer
  • 36. BIOASTER
  • 37. Biocartis
  • 38. Biofortis Mérieux Nutrisciences
  • 39. BioGaia
  • 40. Biogen
  • 41. Biohit
  • 42. Biome360
  • 43. Biomecite Diagnostics
  • 44. BIOMILLENIA
  • 45. BiomX
  • 46. Bio-Rad
  • 47. Biose
  • 48. Biosortia Pharmaceuticals
  • 49. Blue Turtle Bio Technologies
  • 50. Boehringer Ingelheim International
  • 51. Boston Children's Hospital
  • 52. Boston Medical Center
  • 53. Brigham and Women's Hospital
  • 54. Bright Medicine Clinic
  • 55. Bristol-Myers Squibb
  • 56. BTER Foundation
  • 57. C3J Therapeutics
  • 58. Caelus Health
  • 59. Canadian Association of Gastroenterology
  • 60. Canadian Digestive Health Foundation
  • 61. Capsugel
  • 62. Carna Biosciences
  • 63. Cedars-Sinai Medical Center (CSMC)
  • 64. CHAIN Biotechnology
  • 65. Chinese University of Hong Kong
  • 66. Chr. Hansen
  • 67. Cigna
  • 68. Cipac Therapeutics
  • 69. Cipla
  • 70. Cleveland Clinic
  • 71. Clinical-Microbiomics
  • 72. ClostraBio
  • 73. Cobra Biologics
  • 74. Commense (a subsidiary of PureTech Health)
  • 75. CosmosID
  • 76. Crohn's and Colitis Foundation
  • 77. Cykinso
  • 78. Da Volterra
  • 79. Dairy Innovation Australia Limited (DIAL)
  • 80. Danisco
  • 81. Danone
  • 82. Dava Pharmaceuticals
  • 83. Debiopharm
  • 84. Deerfield Management
  • 85. Defense Advanced Research Projects Agency (DARPA)
  • 86. Department of Health and Human Services, US
  • 87. Dermala
  • 88. Diversigen
  • 89. Dutch Ministry of Economic Affairs
  • 90. Eli Lilly
  • 91. EmblemHealth
  • 92. Emulate
  • 93. Enterome bioscience
  • 94. EpiBiome
  • 95. Epiva Biosciences
  • 96. European Society of Clinical Microbiology and Infectious Diseases
  • 97. Evelo Biosciences
  • 98. Evolve Biosystems
  • 99. Evotec
  • 100. ExeGi Pharma
  • 101. Fecal Microbiota Transplantation Workgroup
  • 102. Ferring Pharmaceuticals
  • 103. Finch Therapeutics
  • 104. Flagship Ventures
  • 105. Flora Therapeutics
  • 106. French National Institute for Agriculture Research
  • 107. FUJIFILM Diosynth Biotechnologies
  • 108. Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
  • 109. G.D. Searle
  • 110. Genentech
  • 111. Genetic Analysis
  • 112. Genewiz
  • 113. Genova Diagnostics
  • 114. GMU Microbiome Analysis Center (MBAC), George Mason University
  • 115. Goodgut
  • 116. Google
  • 117. GSK
  • 118. GT Biologics
  • 119. Gujarat Venture Funds
  • 120. Gustave Roussy
  • 121. Gusto Global
  • 122. Hadassah Medical Center
  • 123. HealthNet
  • 124. HealthPartners
  • 125. Hervana
  • 126. Hoffmann-La Roche
  • 127. Horizons Ventures
  • 128. HOST Therabiomics
  • 129. Human Longevity
  • 130. Hunter Holmes McGuire VA Medical Center
  • 131. Hy Laboratories
  • 132. IBM
  • 133. Icahn School of Medicine, Mount Sinai
  • 134. Igen Biotech Group
  • 135. Illumina Accelerator
  • 136. ImClone
  • 137. Immune Biologics
  • 138. ImmuneBiotech
  • 139. Immunex
  • 140. Immuron
  • 141. Indiana University
  • 142. Industrifonden
  • 143. Inserm
  • 144. Institute for Biomedical Research Dr Josep Trueta of Girona, Spain
  • 145. Institute for Clinical and Experimental Medicine
  • 146. Institute of Animal Physiology and Genetics Academy of Science, Czech Republic
  • 147. Institute of Liver and Biliary Sciences, India
  • 148. Instituto Biomar
  • 149. International Agency for Research on Cancer
  • 150. Intract Pharma
  • 151. Intralytix
  • 152. Intrexon
  • 153. Invesco Asset Management
  • 154. Ironwood Pharmaceuticals
  • 155. IS-diagnostics
  • 156. Ixcela
  • 157. J. Craig Venter Institute
  • 158. Janssen
  • 159. Javelin Venture Partners
  • 160. Jinan Central Hospital
  • 161. Johnson & Johnson
  • 162. Kaleido Biosciences
  • 163. Kelsey Research Foundation
  • 164. Kenézy Gyula Korhaz es Rendelointezet
  • 165. Kindstar Global
  • 166. King's College, London
  • 167. KOLU POHAKU TECHNOLOGIES
  • 168. Kurma Partners
  • 169. Lawrence Berkeley National Laboratory
  • 170. Leadiant Biosciences
  • 171. Leading BioSciences
  • 172. Leiden University Medical Center
  • 173. Life Sciences Partners
  • 174. LifeForce Capital
  • 175. Lille Teaching Hospital (CHRU)
  • 176. List Biological Laboratories
  • 177. Longwood Fund and Domain Associates
  • 178. LuinaBio
  • 179. Lundbeckfond Ventures
  • 180. MaaT Pharma
  • 181. Massachusetts General Hospital
  • 182. MatriSys Bioscience
  • 183. Matrix Capital Management
  • 184. Mayo Clinic
  • 185. McMaster University
  • 186. Medeva Pharma Suisse
  • 187. Medical College of Wisconsin
  • 188. Medical University of Graz
  • 189. Memorial Sloan Kettering Cancer Center
  • 190. Merck
  • 191. Metabiomics
  • 192. MetaboGen
  • 193. Metrodora Therapeutics
  • 194. Microbiome Diagnostics
  • 195. Microbiome Health Research Institute
  • 196. Microbiome Insights
  • 197. MicroBiome Therapeutics (formerly NuMe Health)
  • 198. MicrobiomeDX
  • 199. Microbiota Company
  • 200. MicroViable Therapeutics
  • 201. Millennium Pharmaceuticals
  • 202. Miomics
  • 203. Mirna Therapeutics
  • 204. Miskolci Semmelweis Korhaz es Egyetemi Oktatokorhaz
  • 205. Miyarisan Pharmaceutical
  • 206. Molecular Research
  • 207. Monarch Labs
  • 208. Monash University
  • 209. Morgenthaler Ventures
  • 210. MyBiotics
  • 211. Naked Biome
  • 212. National Institute for Health and Care Excellence (NICE)
  • 213. National Institute of Allergy and Infectious Diseases
  • 214. National Institute of Diabetes and Digestive and Kidney Diseases
  • 215. National Institutes of Health
  • 216. Nestlé Health Science
  • 217. New Enterprise Associates
  • 218. New Zealand Society of Gastroenterology
  • 219. Nizo food research
  • 220. Novartis
  • 221. Novo Nordisk
  • 222. NuBiyota
  • 223. NYU Langone Medical Center
  • 224. Odense Patient Explorative Data Network(OPEN)
  • 225. Odense University Hospital
  • 226. Omega Biomics
  • 227. OmniBiome (acquired by Therapeutic Solutions International)
  • 228. One Way Liver (OWL Metabolomics)
  • 229. OpenBiome
  • 230. Oragenics
  • 231. OrbiMed
  • 232. Orexigen Therapeutics
  • 233. Origin Sciences
  • 234. Osel
  • 235. Osi Pharmaceuticals
  • 236. Owlstone Medical
  • 237. OxThera
  • 238. Patheon
  • 239. Perrigo Pharma
  • 240. Pfizer
  • 241. Pharmacia & Upjohn
  • 242. Phi Therapeutics
  • 243. Phylagen
  • 244. Physiogenex
  • 245. Pierre Fabre
  • 246. Prev
  • 247. Prime Value Capital Management
  • 248. Priority Health
  • 249. Procarta Biosystems
  • 250. ProDigests
  • 251. Prometheus Laboratories
  • 252. Public Health England
  • 253. PureFlora
  • 254. Qianfoshan Hospital, China
  • 255. Quay Pharma
  • 256. Quorum Innovations
  • 257. Rambam Health Care Campus
  • 258. Rebiotix
  • 259. Regence Blue Cross Blue Shield
  • 260. Regence Blue Cross Blue Shield of North Carolina
  • 261. Regeneron Pharmaceuticals
  • 262. Region Skane
  • 263. Resilient Biotics
  • 264. Resphera Biosciences
  • 265. RIKEN
  • 266. Rise Therapeutics
  • 267. Ritter Pharmaceuticals
  • 268. Roche Laboratories
  • 269. Rock Springs Capital
  • 270. RondinX
  • 271. Royal Perth Hospital
  • 272. Sandoz (Novartis)
  • 273. Sanofi
  • 274. S-Biomedic
  • 275. SciBac
  • 276. Science 37
  • 277. Seattle Children's Hospital
  • 278. Second Genome
  • 279. Sejtterapia Kozpont
  • 280. Seraph Group
  • 281. Seres Therapeutics
  • 282. Servier
  • 283. Seventure Partners
  • 284. Shandong University
  • 285. Shire
  • 286. Shoreline Biome
  • 287. Sicor
  • 288. Silicon Valley Bank
  • 289. Siolta Therapeutics
  • 290. SLS Venture
  • 291. Spruce Capital Partners
  • 292. SR One
  • 293. St. Joseph's Healthcare Hamilton
  • 294. Stanford University School of Medicine
  • 295. Stason Pharmaceuticals
  • 296. Sucampo
  • 297. SungentBio Venture
  • 298. Sunstone Capital
  • 299. Swecure
  • 300. Symberix
  • 301. Symbiotic Health
  • 302. Symbiotix Biotherapies
  • 303. SynbiCITE
  • 304. Synco Bio Partners
  • 305. Synlogic
  • 306. Synthetic Biologics
  • 307. Szabolcs-Szatmar-Bereg Megyei Korhaz es Egyetemi Oktatokorhaz
  • 308. Taiho Pharmaceutical
  • 309. Takeda Pharmaceutical
  • 310. TargEDys
  • 311. Tate & Lyle Ventures
  • 312. Tech Coast Angels
  • 313. Tel-Aviv Sourasky Medical Center
  • 314. The Bill and Melinda Gates Foundation
  • 315. The BioCollective
  • 316. The Broad Foundation
  • 317. The Danish Rheumatism Association
  • 318. The First Affiliated Hospital of Soochow University
  • 319. The Jackson Laboratory (JAX)
  • 320. The Miriam Hospital
  • 321. The Ohio State University Wexner Medical Center
  • 322. The Psoriasis Association, Denmark
  • 323. The Second Hospital of Shandong University
  • 324. Therabiome
  • 325. Therapeutic Solutions International
  • 326. Thryve
  • 327. Trayer Biotherapeutics
  • 328. Tucana Health
  • 329. uBioDiscovery
  • 330. UCB Pharma
  • 331. UD-Genomed
  • 332. UM Ventures, University of Maryland
  • 333. University of Alberta
  • 334. University of British Columbia
  • 335. University of Calgary
  • 336. University of California, Irvine
  • 337. University of California, Los Angeles
  • 338. University of California, San Francisco
  • 339. University of Cape Town
  • 340. University of Chicago
  • 341. University of Debrecan
  • 342. University of Guelph
  • 343. University of Maryland
  • 344. University of Nebraska
  • 345. University of North Carolina, Chapel Hill
  • 346. University of Pennsylvania
  • 347. University of Rome Tor Vergata, Italy
  • 348. University of Southern Denmark
  • 349. University of Texas Health Science Center, Houston
  • 350. University of Tokyo
  • 351. University of Toulouse
  • 352. University of Wisconsin, Madison
  • 353. Vaiomer
  • 354. Vedanta Biosciences (a subsidiary of PureTech Health)
  • 355. Ventrus Biosciences (merged with Assembly Pharmaceuticals in May 2014)
  • 356. Veristat
  • 357. Vertex Pharmaceuticals
  • 358. Viking Global Investors
  • 359. Viome
  • 360. Virginia Commonwealth University
  • 361. ViThera Pharmaceuticals
  • 362. VIVUS
  • 363. Wavepoint Ventures
  • 364. Weizmann Institute of Science
  • 365. Wellmicro
  • 366. West China School of Stomatology, Sichuan University
  • 367. Whole Biome
  • 368. Wolfson Medical Center
  • 369. World Gastroenterology Organziation
  • 370. Wyss Institute
  • 371. Wyssta Investments
  • 372. Xycrobe Therapeutics
  • 373. Yakult Honsha
  • 374. Yantai Yuhuangding Hospital
  • 375. Ysios Capital
  • 376. Zaluv
Back to Top